Tenofovir alafenamide Fumarate tablets,

Effects and efficacy:
Tenofolate alafenamide fumarate tablets are mainly used to treat chronic hepatitis B and hepatitis B cirrhosis.

Usage and dosage:
Adults and adolescents (age 12 years and above, weight 35 kg and above) take one tablet once a day. Take orally with food. The specific course of treatment is determined by an experienced doctor based on the condition. Precautions for monitoring before and after medication HIV antibody testing should be performed before medication. If positive, an antiretroviral combination therapy suitable for patients with co-infection with HIV-1 should be used. Monitor liver function every 3 months during medication. Liver function (including clinical and laboratory tests) should also be monitored regularly for at least 6 months after stopping anti-hepatitis B treatment, and anti-hepatitis B treatment can be resumed in a timely manner under the guidance of a doctor.

Adverse reactions:
The following adverse reactions may occur after medication. Gastrointestinal diseases: diarrhea, vomiting, nausea, abdominal pain, abdominal distension, flatulence, etc. Systemic diseases: fatigue. Neurological diseases: headache, dizziness. Skin and subcutaneous tissue diseases: rash, pruritus. Hepatobiliary diseases: increased alanine aminotransferase. Musculoskeletal and connective tissue diseases: joint pain. In addition, severe fatty liver enlargement and lactic acidosis (which may manifest as rapid breathing, rapid heartbeat, severe nausea or vomiting, drowsiness, fatigue, severe dizziness, muscle pain or painful cramps, etc.) may occur after taking the drug. If you suspect the above side effects, please seek medical attention in time. In addition to the above adverse reactions, hepatitis may worsen during or after treatment of hepatitis, and severe cases may be fatal. At this time, special attention should be paid: during treatment, the compensated stage of hepatitis may deteriorate to the decompensated stage, and it is not recommended to stop treatment during the progressive stage; some patients may experience a sudden worsening of the progressive disease after stopping hepatitis treatment, and laboratory liver function indicators need to be closely monitored within half a year, and treatment should be resumed if possible.

Drug contraindications:
Allergic to this product is prohibited, children are prohibited, pregnancy is prohibited, and lactation is prohibited.